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(54) Method for prediction of lipoprotein content from NMR data
(57) The invention concerns a method of preparing
regression coefficients for predicting the quantity of a
component of a lipoprotein entity in a biological sample
from NMR spectral data and a method of predicting the
quantity of a component of a lipoprotein entity in a bio-
logical sample from NMR spectral data, which is based
on the regression coefficients. To this end, a spectrally
local multivariate regression analysis is performed on the
basis of a local subspectrum of an NMR spectrum and a
reference quantification of the lipoprotein entity. The in-
vention is especially useful for predicting the triacylglyc-
erol level in chylomicrons of a patient.














Field of the invention
[0001] The present invention relates to a method of
preparing regression coefficients for predicting the quan-
tity of a component of a lipoprotein entity in a biological
sample. In the method a regression model is prepared
from NMR spectra of biological samples from a group of
non-fasting subjects, which samples have been analysed
using a reference quantification method. By comparing
error estimates for NMR subspectra for local multivariate
regression analyses with an error estimate for a global
multivariate regression analysis, a local multivariate re-
gression model may be selected for preparing the regres-
sion coefficients. In one embodiment the multivariate re-
gression analysis is a partial least squares regression
analysis. The method is useful for measuring and mon-
itoring fat uptake as a function of diet, lifestyle, and health
status. The method may be used for assessment and
understanding of disease processes and risks, such as
for predicting a risk of developing a cardiovascular dis-
ease (CVD).
Background of the invention
[0002] It is currently well-known that the risk of devel-
oping a cardiovascular disease (CVD) is correlated with
the presence of lipoproteins and lipoprotein entities in
the blood. Lipoproteins are commonly quantified in blood
samples withdrawn from fasting subjects. However, it is
suspected that blood samples may be advantageously
analysed soon after the ingestion of a meal. In particular,
when triacylglycerols (TAG) are ingested in a meal the
TAGs will usually enter circulation within 15 minutes after
the meal. The TAGs may enter into circulation in the form
of chylomicrons, which generally function to carry TAGs
from the intestines to the liver, skeletal muscle, and to
adipose tissue. Chylomicrons are large, e.g. 75 to 1200
nm, micellar lipoprotein entities, primarily composed of
lipids (e.g. 85%). It is suspected that chylomicrons may
represent a marker for development of CVDs in addition
to other lipoprotein entities.
[0003] WO2005/098463 relates to NMR clinical ana-
lysers and methods and computer programs for analys-
ing NMR spectra from biological samples for e.g. lipo-
proteins. WO2005/098463 suggests to employ multivar-
iate analysis for measuring the lipoprotein classes very
low density lipoproteins (VLDL), low density lipoproteins
(LDL), high density lipoproteins (HDL) and chylomicrons.
However, it is not clear how well the classes may be
predicted and differentiated. In particular
WO2005/098463 does not demonstrate how chylomi-
crons may be measured using the method described
therein. Furthermore, it is not clear if the method of
WO2005/098463 can be used for analysing samples
withdrawn from non-fasting subjects.
[0004] WO2002/086500 relates to the field of metab-
onomics, especially chemometric methods for analysing
samples, e.g. a biological sample. WO2002/086500 is
focused on artherosclerosis and coronary heart disease,
and therefore lipoproteins and subclasses of these are
of interest to WO2002/086500, since these entities are
well-known indicators of risk of these CVDs. Among the
chemometric methods of WO2002/086500 are both un-
supervised, e.g. principal component analysis (CPA),
and supervised (e.g. partial least squares, PLS) methods
for analysis of 1H and 13C NMR spectra.
WO2002/086500 provides descriptions of the mathemat-
ics employed in the chemometric methods, and further-
more examples are given of measurement of lipids and
some lipoprotein entities in biological samples. The re-
sults of the experiments where NMR-spectra of samples
were analysed using supervised multivariate analyses
appear to indicate that the method is not able to differ-
entiate fully between the different lipoprotein entities. For
example, the results may not yield a quantification of chy-
lomicrons in the blood and samples analysed in
WO2002/086500 were derived from subjects having fast-
ed overnight. Thus, it is not evident that the method of
WO2002/086500 may be used to predict chylomicrons
in a sample from a non-fasting subject.
[0005] Petersen et al. (2005, Clin. Chem., 51:8,
1457-1461) employ PLS regression to predict cholesterol
and triglyceride concentrations in plasma as well as in
VLDL, intermediate density lipoproteins (IDL), LDL, 3
LDL fractions, HDL, and 3 HDL subclasses. Samples an-
alysed by Petersen et al. only comprised blood samples
withdrawn from fasting subjects, and the article contains
no indication that the employed method and statistics
may predict chylomicrons.
[0006] There is now a need to provide a better analyt-
ical method to analyse biological samples for contents
of lipoproteins. Especially, there is a need for an analyt-
ical method to analyse for or predict TAG contents in
chylomicrons. Likewise, there is a need to provide an
analytical method capable of quantifying or predicting the
quantity of a lipoprotein or a component of a lipoprotein
entity.
[0007] It is the aim of the present invention to address
these problems.
Summary of the invention
[0008] The present invention relates to a method of
preparing a regression model for predicting the quantity
of a component of a lipoprotein entity in a biological sam-
ple; the method comprises the steps of:
- providing biological samples from a group of non-
fasting vertebrate subjects;
- quantifying the lipoprotein entity in the biological
samples using a reference quantification method;
- recording NMR spectra of the biological samples;
- subjecting the NMR spectra to a global multivariate
regression analysis;
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- dividing the range of chemical shifts of the NMR
spectra into a number of intervals to obtain NMR
subspectra, each corresponding to a given interval
of chemical shifts;
- subjecting the NMR subspectra for each interval of
chemical shifts to a local multivariate regression
analysis;
- calculating error estimates for the global multivariate
regression analysis and for each of the local multi-
variate regression analyses for the lipoprotein entity
as quantified using the reference quantification
method;
- selecting an interval of chemical shifts based on a
comparison of the error estimates of the local multi-
variate regression analyses with the error estimate
for the global multivariate regression analysis; and
- calculating regression coefficients for the local mul-
tivariate regression analysis corresponding to the
selected interval.
[0009] The method of the invention is based on a sta-
tistical analysis, a multivariate statistical analysis, of a
large number of biological samples, which are analysed
using a reference quantification method. The statistical
analysis of the reference quantification may be used as
a basis to prepare regression coefficients for predicting
the quantity of a component of a lipoprotein entity in a
biological sample. Prediction of the quantity of a compo-
nent of a lipoprotein entity is relevant for any vertebrate
subject, although mammalian vertebrate subjects are
preferred. In a certain embodiment the vertebrate subject
is human. Lipoproteins and lipoprotein entities are gen-
erally indicative of cardiovascular diseases (CVD) and
may be used to estimate the risk of an individual of ac-
quiring such disease. In particular, measurement and
monitoring of uptake of fat or lipids as a function of pa-
rameters such as diet, lifestyle, and health status may
be relevant for estimating this risk. The method of the
invention advantageously allows analysis of a sample
from a non-fasting subject, thus providing data not pre-
viously available. Prediction of the quantity of a compo-
nent of any lipoprotein entity, such as of chylomicrons,
of very low density lipoproteins (VLDL), of intermediate
density lipoproteins (IDL), of low density lipoproteins
(LDL), and of high density lipoproteins (HDL) etc. may
thus be considered indicative of the disease and/or health
state of an individual, and are therefore relevant for the
present invention. However, it is preferred that the lipo-
protein entity is a chylomicron. Likewise, it is relevant to
predict any component of the lipoprotein entity, although
it is preferred that the lipoprotein entity is triacylglycerol.
[0010] Any reference quantification method which may
quantify the component of the lipoprotein entity may be
used in the method of the invention. In one embodiment
the reference quantification method is an ultracentrifu-
gation method.
[0011] Any biological sample from the vertebrate sub-
ject may be employed for quantifying the lipoprotein entity
in the biological samples using the reference quantifica-
tion method, although it is preferred that the sample is
blood, serum or plasma or derived from these. In partic-
ular, it is preferred to provide the biological sample from
a non-fasting vertebrate subject. It is further preferred
that the sample is fresh. Analysis of a sample from a non-
fasting subject may provide additional information not
available from the traditional analysis of samples with-
drawn from fasting subjects. For example, analysis of
samples from non-fasting subjects may give an improved
estimate of the disease and/or health state of the subject.
[0012] The regression coefficients for predicting the
quantity of a component of a lipoprotein entity are ob-
tained by comparing the quantification results obtained
using the reference quantification method with NMR
spectra recorded for the biological samples. Any type of
NMR spectra may be subjected to this analytical ap-
proach, although it is preferred to subject proton NMR
spectra or phosphorus NMR spectra to the analysis. 1H
or 31P NMR spectra are highly relevant for biological
samples due to the high natural abundance of these two
isotopes; although a 13C NMR spectrum may also be
used. It is further preferred that the spectra are one-di-
mensional, and the spectra may be recorded with or with-
out solvent (e.g. water) suppression. In the method of
the invention, the NMR spectra will be subjected to a
global multivariate regression analysis. Subsequently,
the range of chemical shifts of the NMR spectra is divided
into a number of intervals to obtain NMR subspectra,
each corresponding to a given interval of chemical shifts.
The range of chemical shifts may be divided into any
number of intervals; it is preferred that the intervals are
equidistant, although this is not a requirement. For ex-
ample, a NMR (1H) spectrum with chemical shifts ranging
from 0.0 to 5.8 ppm may be divided into 16 equidistant
intervals. The NMR subspectrum for each interval of
chemical shifts is then subjected to a local multivariate
regression analysis. This will allow error estimates to be
calculated for each local multivariate regression analysis
and compare this to the error estimate for the global mul-
tivariate regression analysis. Any multivariate regression
analysis may be used in the method; in a specific em-
bodiment the multivariate regression analysis is a partial
least squares (PLS) regression analysis. Thus, in the
method of the invention these error estimates are calcu-
lated for the lipoprotein entity as quantified using the ref-
erence quantification method. Error estimates may for
example be expressed as the root mean squared error
of cross-validation (RMSECV) or any other statistical pa-
rameter for expressing error estimates. The error esti-
mate for each of the local multivariate regression analy-
ses may be compared to the global multivariate regres-
sion analysis, and the inventors have now found that for
certain intervals of chemical shifts the local multivariate
regression analysis may yield a better error estimate, e.g.
as expressed by a lower RMSECV, than found for the
global multivariate regression analysis. According to the
method of the invention an interval of chemical shifts
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based on the comparison of the error estimates of the
local multivariate regression analyses with the error es-
timate for the global multivariate regression analysis is
now selected, and regression coefficients for this local
multivariate regression analysis are then calculated. In
one embodiment of the invention an interval correspond-
ing to the chemical shifts comprising the lipid methylene
and/or the methyl resonance(s) is(are) selected. Thus,
for example the spectral region of 1.05 ppm to 1.4 ppm
may be selected for calculation of the regression coeffi-
cients for the local multivariate regression analysis, e.g.
PLS regression analysis.
[0013] In another aspect the invention relates to a
method of predicting the quantity of a component of a
lipoprotein entity in a biological sample using the regres-
sion coefficients obtained in the first aspect of the inven-
tion. In this second aspect the method therefore compris-
es the steps of:
- providing a biological sample from a non-fasting ver-
tebrate subject;
- recording a NMR spectrum of the biological sample;
- selecting an interval of chemical shifts;
- comparing the NMR subspectrum corresponding to
the selected interval of chemical shifts with a model
employing regression coefficients obtainable in the
method of the first aspect;
- predicting the quantity of the component of the lipo-
protein entity by the use of the regression coeffi-
cients.
[0014] The vertebrate subject will be of the same spe-
cies as the group of vertebrate subjects providing the
samples used to calculate the regression coefficients,
and any of the above considerations for the method of
the first aspect also apply to the method of this second
aspect.
[0015] In yet another aspect, the invention relates to a
NMR analyser for predicting the quantity of a component
of a lipoprotein entity, the analyser comprising
- a NMR spectrometer for recording a NMR spectrum;
- a computer readable storage medium containing a
regression model for predicting the quantity of a li-
poprotein entity prepared in a method according to
the first aspect of the invention, and computer pro-
gram code configured to predict the quantity of the
lipoprotein entity using the regression model; and
- a data processor for executing the computer pro-
gram code.
[0016] In general, the NMR analyser may comprise
any type of NMR spectrometer, although it is preferred
that the NMR spectrometer is equipped for recording a
proton (1H) NMR spectrum or a phosphorus (31P) NMR
spectrum. The NMR spectrometer may also be equipped
for recording a carbon (13C) NMR spectrum. The NMR
spectrometer may operate at any frequency, for example
the NMR spectrometer may operate at or above 1H Lar-
mor frequencies of 200 MHz, such as at frequencies of
about 200, 300, 400, 500, or 600 MHz etc.
[0017] The computer readable storage medium will
typically be a medium allowing data obtained in the anal-
ysis to be stored thereon. For example, a data set ob-
tained in the analysis may contain up to 100,000 data
points or more. Likewise, the regression model contain-
ing the regression coefficients may also be stored on a
storage medium allowing data to be deleted and replaced
so that the regression coefficients may be replaced with
a newer, e.g. improved, regression model. It is however,
also possible that the regression model is stored on a
replaceable storage medium of a "read-only" type so that
the read-only storage medium with the regression model
may be replaced with another storage medium with a
newer regression model.
[0018] The data processor for executing the computer
program code should be able to handle the NMR data
obtained using the computer program code on the stor-
age medium. The computer program code should thus
be capable of obtaining the NMR spectrum, e.g. as data
points representing the NMR spectrum, apply the NMR
spectrum in the regression model and provide a predic-
tion of the quantity of the component of the lipoprotein
entity. The lipoprotein entity is preferably a chylomicron,
and the component of a lipoprotein entity preferably a
triacylglycerol. The NMR analyser may also have a user
interface, comprising e.g. a screen or a printer, for pre-
senting the prediction of the quantity of the lipoprotein
entity to an operator. The user interface may also com-
prise data input means for providing other data to the
data processor.
[0019] In one embodiment of this aspect, the computer
readable storage medium further contains a model for
predicting the risk of a given subject for developing a
disease based on the prediction of the quantity of the
lipoprotein entity. Relevant diseases, the risk of which
may be predicted from the lipoprotein entity, are any type
of CVDs. Thus, the NMR analyser of this embodiment
can analyse a sample from a subject to predict a quantity
of a component of a lipoprotein entity from the NMR spec-
trum obtained using the regression coefficients. This pre-
diction may in turn be used to predict the risk of the subject
for developing CVD, and the risk may then be commu-
nicated to the subject.
[0020] The NMR analyser of the invention may also
comprise a connection to a network of computers. Such
a network may comprise computers, e.g. "servers", ca-
pable of replacing the regression model of the NMR an-
alyser with another, e.g. improved, regression model.
The analyser may also be capable of communicating re-
corded NMR spectra to the servers. This communication
between NMR analysers in a network and servers may
then be used to further improve a regression model of
the invention.
[0021] It is advantageous that the method of the inven-
tion is transferable from spectrometer to spectrometer
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and from laboratory to laboratory. Therefore in a pre-
ferred variant of the invention the method further com-
prises steps to ensure transferability; these steps may
include specifications of protocols for sample prepara-
tion, e.g. from blood, plasma, serum etc., specifications
of storage conditions of the samples, and specifications
of NMR sample preparation protocols. Likewise, the
NMR spectrometer may also be specified together with
operational parameters, as well as procedures and pro-
tocols for calibration of the NMR spectrometer. The
processing of the NMR data may also be specified to-
gether with quality parameters for the NMR data (e.g.
line shape and line width, allowed positional variability of
predefined signals, signal-to-noise). In particular, the ob-
jective of this embodiment is that any variability created
by any of the experimental procedures and steps in-
volved is significantly smaller than the variability related
to the concentration of the lipoprotein entity, e.g. chylom-
icrons, or the component of the lipoprotein entity, e.g.
triacylglycerol. Transferability may be demonstrated via
instrument and inter-lab cross-calibration tests.
Brief description of the drawings
[0022]
Fig. 1 A representative NMR spectrum of human
blood covering the entire lipid region from 0.0 ppm
to 5.8 ppm. Insert shows a schematic view of the
micellar chylomicron structure.
Fig. 2 An iPLS regression model. Insert A shows the
methylene peak according to the sample content of
chylomicron TAG. Insert B show the regressions co-
efficients of the iPLS models together with an aver-
age spectrum of 153 blood samples.
Fig. 3 An iPLS regression model as viewed by a pre-
dicted (NMR-TAG) versus measured (UC-TAG) plot.
Detailed description of the invention
[0023] The present invention relates to a method of
preparing regression coefficients for predicting the quan-
tity of a component of a lipoprotein entity in a biological
sample; the invention also relates to a method of predict-
ing the quantity of a component of a lipoprotein entity in
a biological sample using the regression coefficients and
to an NMR analyser for predicting the quantity of a lipo-
protein entity. The invention will now be described in more
detail referring to specific embodiments. In order to more
fully explain the invention, definitions of the terms em-
ployed in this document are given below.
[0024] In the context of the present invention the term
"lipoproteins entity" refers to any entity found in bodily
fluids, such as blood or serum, of a vertebrate subject,
e.g. a human being or a mammal, comprising lipids and
proteins. Thus, a lipoprotein entity is typically an assem-
bly of lipids and proteins where hydrophobic lipids or lipid
derivatives are surrounded by a shell of proteins provid-
ing a hydrophilic outer surface to the assembly. This hy-
drophilic outer surface helps solubilise the lipids in the
aqueous bodily fluid, e.g. blood or serum, and the lipo-
protein entities generally function to transport lipids
around in the vertebrate body. Lipoproteins may be clas-
sified according to size and density into chylomicrons,
very low density lipoproteins (VLDL), intermediate den-
sity lipoproteins (IDL), low density lipoproteins (LDL), and
high density lipoproteins (HDL); the classification and the
characteristics of the lipoprotein entities is well-described
in the literature (see for example JM Berg; JL Tymoczko;
L Stryer, Biochemistry, 6th Edition, W.H. Freeman, 2007,
New York). A lipoprotein entity may also be referred to
as a lipoprotein particle, and the terms may be employed
interchangeably. Chylomicrons are preferred as lipopro-
tein entities in the context of the present invention.
[0025] A "component of a lipoprotein entity" may be
any component found in the lipoprotein entity. Examples
of such components are cholesterol, triglycerides, tria-
cylglycerides (TAG) etc.
[0026] In a certain embodiment of the method of the
invention, the sample is a fresh sample, e.g. a fresh blood
sample. In this context "fresh" refers to a sample, which
has not been frozen between withdrawal from the subject
and analysis. A sample containing other added substanc-
es, such as anticoagulants, e.g. citrate or EDTA, or pre-
servatives, such as sodium azide, is also considered
"fresh" if it has not been frozen between withdrawal and
analysis.
[0027] It is preferred that a sample for analysis in the
method of the present invention is withdrawn from a non-
fasting subject. In the context of the invention "non-fast-
ing" means that the sample is withdrawn from a subject
which does not need to be in a fasting state. A fasting
state may occur when the subject is required not to ingest
any food in a specified amount of time, such as 6 hours,
12 hours or another specified amount of time, before with-
drawing the sample. Thus, when a sample is withdrawn
without regard to when the subject ingested food it may
be considered to be withdrawn from a non-fasting sub-
ject. However, in a specific embodiment the sample is
withdrawn at a specified amount of time after the subject
has ingested food, e.g. a meal, such as for example 5,
10, 20 or 30 minutes, 1, 2 or 3 hours etc. after ingestion.
In yet another embodiment the subject ingests a defined
test meal before withdrawing the sample at the specified
point of time. A defined test meal may for example contain
a specified amount of energy, such as 2, 3, 4, 5 or 6 MJ
with a predetermined macronutrient composition, e.g.
15% of the energy (or E%) from protein, 35E% from fat
and 50E% from carbohydrates. The defined test meal
may also contain indigestible components, such as die-
tary fibre, e.g. in the range from 0 to 15 g.
[0028] The method of the invention refers to a "refer-
ence quantification method". This term covers any quan-
tification method that may be employed to quantify a com-
ponent, such as a component of a lipoprotein entity, in a
biological sample. In particular, for the analysis of com-
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ponents, such as TAGs, in samples from blood or serum
or the like, methods capable of separating analytes
based on parameters such as size and density are rele-
vant. A preferred reference quantification method is ul-
tracentrifugation, or differential centrifugation; this meth-
od is described in more detail in e.g. Baumstark MW,
Kreutz W, Berg A, Frey I, Keul J. Structure of human low-
density lipoprotein subfractions, determined by X-ray
small-angle scattering, Biochim. Biophys. Acta 1990;
1037:48-57.
[0029] The method of the invention employs a multi-
variate data analysis. A preferred method is the one
known as partial least squares (PLS) regression analysis.
Other relevant multivariate regression analyses are col-
linear ridge regression and principal component regres-
sion (PCR), although the invention is not limited to these.
Multivariate analysis may advantageously project multi-
variate data into few dimensions, e.g. in a graphical in-
terface. A general purpose of the multivariate data anal-
ysis as used in the present invention is to optimise the
predictive power of multivariate data analysis regression
models, such as PLS models, and to aid in interpretation.
The concepts and terms employed in this context are
explained below, also in connection with other parame-
ters and models employed in multivariate data analysis.
[0030] "Partial least squares regression" (PLS) is a
predictive two-block regression method based on esti-
mated latent variables and is applied to the simultaneous
analysis of two data sets (e.g., spectra and physical/
chemical tests) on the same objects (H. Martens and T.
Næs, Multivariate Calibration (Wiley, New York, 1993),
2nd ed) (e.g., samples of beer or fruit juice). The purpose
of the PLS regression is to build a linear model enabling
prediction of a desired characteristic (y) from a measured
spectrum (x). In matrix notation we have the linear model
y = Xb where b contains the regression coefficients that
are determined during the calibration step, and X is the
matrix of collected spectra. PLS was first applied to eval-
uate NIR spectra by Martens and Jensen in 1983, ("Par-
tial Least Squares Regression: A New Two Stage NIR
Calibration Method" , in Progress in Cereal Chemistry
and Technology, J. Holas and J. Kratochvil, Eds. (Else-
vier, Amsterdam, 1983), pp. 607-647) and is now used
routinely in academia and industry to correlate (rapid)
spectroscopic measurements with related chemical/
physical data.
[0031] "Interval PLS" (iPLS) is an interactive extension
to PLS, which develops local PLS models on equidistant
subintervals of the full-spectrum region. Its main force is
to provide an overall picture of the relevant information
in different spectral subdivisions, thereby focusing on im-
portant spectral regions and removing interferences from
other regions. The sensitivity of the PLS algorithm to
noisy variables is highlighted by the informative iPLS
plots. Interval PLS models are developed on spectral
subintervals of equal width, and the prediction perform-
ance of these local models and the global (full-spectrum)
model is compared. The comparison is mainly based on
the validation parameter RMSECV (root mean squared
error of cross-validation), but other parameters such as
r2 (squared correlation coefficient), slope, and offset are
also evaluated to ensure a comprehensive model over-
view. Sample and/or measurement abnormalities (out-
liers) as detected by PLS inner relation plots should gen-
erally be removed prior to the application of iPLS. Models
based upon the various intervals (Xinterval) usually need
a different number of PLS components than do full-spec-
trum models to catch the relevant variation in y. This con-
dition is caused by the varying amount of y-correlated
information carried by the interval variables (the larger
the spectral interval, the greater the number of substanc-
es that are likely to absorb/interfere) and is also related
to the noise/interference carried by the variables. How-
ever, the selected model dimension has to be common
to all the local models in order to make a comparison
possible. In order to favor the "best" spectral region, it is
natural to let the simplest interval model (i.e., the one
with the smallest number of PLS components) guide the
selection of the model dimension. A fair comparison of
the global and local models requires that the global and
local model dimensions be selected separately.
[0032] Simple Optimization of the Best Interval from
Equidistant iPLS. There is a minimal probability for hitting
the optimal interval with the equidistant subdivisions. A
more optimal interval might be found by carrying out small
adjustments in the interval limits. The optimization per-
formed consists of the following steps: (1) interval shift;
(2) changes in interval width: two-sided (symmetrical),
one-sided (asymmetrical, left), or one-sided (asymmet-
rical, right). Each step is initiated with the optimal interval
limits from the previous step. The interval limits are
changed one variable at a time and evaluated by the
RMSECV provided by application of PLS regression to
the interval; this approach works in practice but could be
done more elegantly.
Error Measures
[0033] The "root mean square error" (RMSE) in com-
bination with the correlation coefficient (r) is used as a
measure of how a given model performs. RMSE is de-
fined as follows: 
where yprea is the predicted value, yref is the laboratory
measured value, and N is the number of samples.
[0034] RMSEC is RMSE calculated from the calibra-
tion samples, i.e., a measure of fit. RMSECV is calculated
from the cross-validated samples, and RMSEP is calcu-
lated from the independent test (or prediction) set (H.
Martens and T. Næs, Multivariate Calibration (Wiley,
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New York, 1993), 2nd ed., S. Wold, Technometrics 20,
397 (1978)). Correspondingly, rcal, rcv, and rpred are the
correlation coefficients for these three situations.
[0035] The inventors have now found that a method
based on the iPLS method described above may be em-
ployed to provide an improved regression model for pre-
dicting the quantity of a component of a lipoprotein entity
in a biological sample as compared to methods known
in the prior art.
[0036] A preferred embodiment of the method com-
prises providing biological samples from a group of non-
fasting vertebrate subjects. The vertebrate subjects may
be humans, and the samples may be blood samples. For
example, blood samples may be withdrawn into tubes
containing EDTA, or another compound preventing co-
agulation of the blood; the samples may also be plasma
obtained from the blood samples, e.g. as a supernatant
from a centrifugation of the blood.
[0037] The lipoprotein entity is then quantified in the
biological samples. For example, chylomicrons may be
isolated from plasma in an ultracentrifugation step,
wherein the plasma is initially overlayed on a salt solution,
e.g. of a density 1.006 kg/l. The tubes are then centri-
fuged in an ultracentrifuge, e.g. at 23 minutes at 30.000
rpm. A relevant ultracentrifuge is an L7-55 from Beck-
mann Instruments (Palo Alto, CA) using a fixed angle
rotor (50.4 Ti, Beckmann Instruments). Following ultra-
centrifugation the tubes may be sliced at e.g. 45 mm from
the bottom, and the TAG concentration measured in the
chylomicron (top) and bottom fractions. Total TAG in the
plasma sample may be analysed by a colorimetric test
kits (Roche TG, Roche Diagnostics GmbH, Mannheim,
Germany).
[0038] For a group of biological samples analysed us-
ing the reference quantification method NMR spectra are
then recorded. For example, proton (1H) NMR spectra
may be recorded on a NMR spectrometer, such as a
Bruker Avance 500 spectrometer; this spectrometer op-
erates at a Larmor frequency of 500.13 MHz for 1H. The
NMR spectra may be recorded using 64 or 128 scans or
more and a relaxation time of up to 20 s, e.g. 5 s. It is
also possible to reduce the number of scans to e.g. 4 to
8 scans. The NMR spectra may also be phosphorus (31P)
NMR spectra or carbon (13C) spectra.
[0039] In a specific setting the Bruker Avance 500
spectrometer was operated as follows (at a magnetic flux
density of 11.75 T and a temperature of 310 K):
[0040] The spectra were recorded using presaturation
followed by a composite 90 degree pulse. The relaxation
delay was 5 s during which presaturation was employed
using a transmitter position at 4.700 ppm. The 90 degree
pulses had duration of 8.0 Ps. The acquisition time was
1.573 s acquired as 32k data points using a spectral width
of 10416.667 Hz (20.8278 ppm). After 2 dummy scans
a total of 64 scans were acquired, requiring 7 min. 21 sec
of measurement time for each sample. Prior to Fourier
transformation each FID was zero filled to 64k points and
apodized by a Lorentzian linebroadening of 0.3 Hz.
Phase correction and baseline correction were per-
formed manually. All spectra were referenced to the ano-
meric proton of α-D-Glucose at 5.23 ppm. Receiver gain
was kept constant.
[0041] Other settings are also possible, and the NMR
parameters and their settings are generally well-known
within the art.
[0042] The NMR spectra are now correlated with the
quantification results obtained using the reference quan-
tification method, e.g. the ultracentrifugation, by subject-
ing the NMR spectra to a global multivariate regression
analysis, e.g. PLS regression analysis. Any number of
components may be used in the calculation of the global
multivariate regression analysis (e.g. PLS) regression
analysis; for example, the global multivariate regression
analysis regression analysis may use 1, 2, 3, 4, 5, 6, 7,
8, 9, 10 or more components.
[0043] The NMR spectra are now divided into a
number of subspectra, by dividing the range of chemical
shifts of the NMR spectra into a number of intervals with
each corresponding to a given interval. A local multivar-
iate (e.g. PLS) regression analysis is then calculated for
each interval, and as for the global regression analysis
any number of components may be used in the calcula-
tion, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more components.
[0044] Error estimates are calculated for the global and
the local regression analysis models. As an example, a
global PLS regression analysis for the analysis of TAG
correlated with TAG analysed by ultracentrifugation
yielded an r2 of 0.90 and a RMSECV of 0.174 mg/g TAG
using 3 principal components. In comparison, the NMR
spectra were divided into 16 intervals, and it was found
that for the interval centered at about 1.28 ppm (in this
instance corresponding to a spectral region of chemical
shifts from 1.05-1.4 ppm), i.e. the methylene peak, an r2
of 0.92 and a RMSECV of 0.156 mg/g TAG was obtained
using 3 principal components. Thus, this local PLS anal-
ysis yielded a better result for predicting TAG in the blood
samples than the global PLS analysis, and the interval
of chemical shifts from 1.05-1.4 ppm was selected for
calculation of the regression coefficients.
[0045] The thus provided regression coefficients may
now be employed in the second aspect of the invention
to predict the quantity of a component of a lipoprotein
entity in a biological sample. In this case, a blood sample
is withdraw from a subject and a proton NMR spectrum
is recorded for the blood sample. The NMR spectrum is
now compared with the regression model to predict the
quantity of TAG of chylomicrons in the sample.
[0046] The invention may be used to estimate an indi-
vidual’s health and/or disease state to determine a risk
of CVDs for that individual. The method may also be em-
ployed to estimate the capacity of an ingredient or com-
ponent of food to diminish lipid uptake, TAG-rich lipopro-
teins, and in particular chylomicrons by measuring these
after ingestion of food containing a relevant component
or ingredient.
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Nuclear Magnetic Resonance and Chemometrics Pre-
dicts Chylomicron TAGs in Human Blood
[0047] Most of our current knowledge on the link be-
tween lipids, lipoprotein metabolism and cardiovascular
diseases (CVD) development rely on observations made
on fasting individuals. Ironically, we spend the vast ma-
jority of our time in a non-fasting postprandial state and
recent studies indicate the existence of a relation be-
tween the risk for developing CVD and postprandial tri-
acylglycerols (TAGs) (1). When fat is absorbed in the
human body it enters the circulation in the form of intes-
tinally derived TAG-rich lipoproteins, essentially chylom-
icrons, usually within about 15 minutes after finishing a
meal. The chylomicrons are released by exocytosis in
the villi of the small intestine, and are then secreted into
the bloodstream at the thoracic duct’s connection with
the left subclavian vein. Chylomicrons are large micellar
lipoproteins, having a diameter of 75 to 1200 nm, and
are primarily composed of triglycerides (85%) and con-
tain some cholesterol and cholesteryl esters (Figure 1
insert). Chylomicrons transport exogenous lipids to liver,
adipose, cardiac and skeletal muscle tissue where their
triglyceride components are unloaded by the activity of
lipoprotein lipase resulting in cholesterol ester-enriched
chylomicron remnants, which may internalize in the ar-
teries smooth muscle cells and take part in plaque for-
mation (2). Chylomicrons gather on arterial walls and
may be as dangerous as low-density lipoprotein (LDL)
cholesterol in causing strokes and heart attacks. Until
now LDL cholesterol, which is produced in the liver and
delivered to the rest of the body over a period of days
after food is ingested, is the primary suspect among cho-
lesterols in the development of coronary artery disease
(3). However, it remains elusive why 40% of people who
are highly vulnerable to suffering a stroke or heart attacks
have low or normal LDL levels. To determine an individ-
ual’s ability to clear postprandial lipids or the capacity of
a food ingredient to diminish lipid uptake, TAG-rich lipo-
proteins, and in particular chylomicrons can be measured
after an oral fat load.
[0048] The gold standard analytical method for meas-
uring TAG-rich lipoproteins is density gradient ultracen-
trifugation (UC). This analysis is very labor-intensive and
requires 24 hours of analysis to fractionate the lipopro-
teins. The number of samples that can be analyzed at
the same time is small due the limited capacity of the
individual ultracentrifuge. Thus, postprandial lipoprotein
metabolism is very limited in large clinical trials. Recently,
Tsai et al (4) showed that Nuclear Magnetic Resonance
(NMR) spectroscopy may represent an alternative meth-
od for the measurement of postprandial TAG-rich lipo-
proteins in humans. In this paper we will demonstrate,
using supervised multivariate pattern recognition on a
large sample set, that the quantification of TAG in chy-
lomicrons can be made very precisely and efficiently. The
results are validated against the UC method. To demon-
strate the performance of the new method, human blood
samples were obtained after ingestion of test meals var-
ying in fiber content, as dietary fibers are known to affect
postprandial lipoprotein responses (5).
[0049] Proton NMR (1H-NMR) spectroscopy has be-
come an indispensable analytical technique for charac-
terization of complex biological samples such as metab-
olite mapping in tissue and body fluids (6). Lipoproteins
have quite similar compositions and thus their subgroups
give rise to very similar NMR signals. However, it has
been shown that NMR signals of lipoproteins in blood are
minimally shifted in frequency due to the different densi-
ties of the lipoproteins giving rise to different local mag-
netic fields (7). Extraction of quantitative information from
NMR spectra normally require curve fitting and/or inte-
gration of peaks, but for optimal extraction of information
in complex matrices a supervised multivariate data min-
ing approach is required such as was employed for lipo-
protein subgroups in human blood (8).
[0050] The mathematical basis for the fundamental ad-
vances in high throughput metabonomic in particular (9)
and quantitative spectroscopy in general has largely
been due to the use of multivariate models such as prin-
cipal component analysis (PCA) (10) and partial least
squares regression (PLS) (11), and facilitated by the on-
going computerized revolution. These techniques, based
on latent variables, facilitate an inductive exploratory
strategy, which is of fundamental scientific importance
as a complement to the ubiquitous deductive research
strategies (12). PCA and PLS use a two-dimensional
multivariate data evaluation strategy, in which many
homologues samples are analyzed simultaneously, in or-
der to extract underlying latent features and to benefit
from the first order data advantage (noise reduction, out-
lier detection, interference compensation). PLS regres-
sion applies to the simultaneous analysis of two sets of
variables on the same objects and is used in quantitative
spectroscopy to correlate the spectroscopic data
(X-block - fast multivariate measurements) to a univariate
physico-chemical data (y-block - time consuming and la-
borious measurements). The main purpose of the regres-
sion is to build a model enabling the prediction of the
reference UC-TAGs characteristic (y) from a measured
NMR spectrum (x). In matrix notation we have the linear
model y = Xb, where b contains the regression coeffi-
cients that are determined during the calibration step.
The PLS-calculation starts with a covariance based cal-
culation and, when using mean centered data, the ele-
ments of the first latent PLS-factor (calculated as X’y)
will be proportional to the covariance of the spectral in-
tensities of X with respect to the y vector of reference
measurements. This illustrates that the information in the
X matrix will be extracted guided, or supervised, by the
information in y.
[0051] A representative NMR spectrum (0.0-5.8 ppm)
of human blood is shown in Figure 1 including peak as-
signment of all the important resonances. This region of
13 14 













the spectrum shows all the broad peaks from lipoprotein
TAGs from the strong methyl and methylene resonances
respectively centered at 0.87 ppm and 1.28 ppm, respec-
tively, to the broad olefinic resonance at 5.30 ppm with
the characteristic overlap with the blood alpha-glucose
doublet. Cholesterol methylene resonances are visible
at the right sidelobe of the methyl peak at 0.69 ppm. Be-
sides the lipid signals the considered region contains in-
formation from the blood sugars, the peptide side-chains
and from the EDTA (Ethylenediaminetetraacetic acid)
used to prevent the plasma from coagulate.
[0052] This report is a part of a larger experimental
design investigating the postprandial lipoprotein re-
sponse as a function of dietary fiber intake. In this study
reference blood samples were drawn after 12 hours of
fasting (0 minutes), after which the subjects ingested a
test meal within 20 minutes and additional blood samples
were drawn at 120, 180, 240 and 300 minutes. The study
protocol was approved by the Municipal Ethical Commit-
tee of Copenhagen and Frederiksberg (Journal no. KF
01-309595). The iso-caloric single test meals provided 4
MJ with the macronutrient composition (15E% from pro-
tein, 35E% from fat and 50E% from carbohydrates) but
dietary fiber intake ranged from 0 to 15 g. The blood sam-
ples were collected in tubes containing EDTA and placed
on ice immediately. The samples were centrifuged at
2800g for 15 minutes at 4°C. Plasma was extracted and
stored overnight at 4°C before NMR analysis. Chylomi-
crons were isolated by careful over-laying 3 ml of plasma
with 2.5 ml salt solution of density 1.006 kg/I. The UC
tubes were centrifuged for 23 minutes at 30.000 rpm in
an ultracentrifuge. The tubes were then sliced 45 mm
from the bottom, and the TAG concentration was meas-
ured by the chylomicron top and bottom fractions con-
taining the smaller lipoproteins and a plasma sample (to-
tal TAG) by a colorimetric test kit. The intra- and inte-
rassay CVs were 0.6% and 1.4%, respectively. Samples
for NMR analysis were prepared by mixing 500 Pl plasma
and 60 Pl D2O.
1H NMR spectra were acquired at 37°C
on a Bruker Avance 500 spectrometer operating at a Lar-
mor frequency of 500.13 MHz for 1H using a 120 Pl flow-
probe. A pulse sequence using presaturation followed
by a composite pulse was used to obtain optimum water
suppression. All spectra were acquired employing a
spectral width of 10417 Hz, an acquisition time of 1.57
s, a relaxation delay of 5 s and 64 scans.
[0053] The study design yielded a total of 623 plasma
samples to be measured by NMR spectroscopy out of
which 153 samples were selected for UC-TAG measure-
ments for calibrating the PLS regression model. The re-
sulting PLS calibration model using the entire spectral
information to develop the PLS model yielded a resulting
correlation coefficient, r2, of 0.90 and a root-mean-
square-error-of-cross-validation (RMSECV) of 0.174
mg/g TAG using just 3 principal components. This result
should be compared to a standard deviation of 0.2 mg/g
TAG on the ultracentrifugation TAG reference. While this
result is exceptionally encouraging an attempt to improve
the model and its interpretation was made by application
of interval Partial Least Squares (iPLS) regression (13).
In this extension to PLS the NMR spectra are divided up
into a number of small regions or intervals for each of
which a local PLS regression model is calculated. The
results of this method are summarized in Figure 2. The
horizontal stipulated line shows the RMSECV perform-
ance of the global PLS model mentioned above (0.17
mg/g TAG) and the bars show the performances (in term
of prediction accuracy) of each of the spectral intervals.
Evidently only two spectral regions are able to improve
the regression model, when compared to the global re-
gression model: one region which include the vicinal
methylene groups to the estergroups of the TAGs and
one region which includes the (poly)-methylene protons
at centered at 1.28 ppm. The latter region give rise to the
best and most parsimonious model for predicting the chy-
lomicron TAGs with a correlation coefficient, r2, of 0.92
and a RMSECV of 0.156 mg/g TAG using only 3 principal
components.
[0054] The iPLS regression model outlined in Figure
2 is extraordinary strong (explaning 92% percent of the
spectral variation) taking into consideration the complex
nature of the samples and the laborious reference pro-
cedure. The insert (above) in Figure 2 shows the 153
superimposed NMR spectra in this spectral region in
which the spectra are colored according to the sample
UC-TAG values. This type of interactive data visualiza-
tion is sometimes very illustrative and it clearly reveals
that there is a systematic trend relating higher intensity
to higher UC-TAG. Scrutinizing the model it is also found
that there is a trend of a higher UC-TAG the more shifted
towards higher ppm. However, no univariate model can
provide a comparable prediction model. The second in-
sert (below) shows a plot of the regression coefficients
(i.e. the variables that are most dominant in the prediction
model) superimposed to the average spectrum of the 153
samples. The plot underlines the advantage of multivar-
iate modeling. In this model the methylene protons of the
chylomicron TAGs are in a "cage of covariance" and the
regression coefficients appear as a much more well-de-
fined (poly)-methylene spectrum than the average spec-
trum.
[0055] The scatter plot in Figure 3 represents the gold-
en proof of this application. In this plot the predicted TAG
values from the 3 component PLS model based on the
NMR spectra are plotted against the measured TAG val-
ues by ultracentrifugation. The point scatter around the
ideal target line (x=y) demonstrates this excellent corre-
lation.
[0056] With the escalating obesity epidemic and its co-
morbidities and the established relationship between
postprandial elevation of lipids and CVD risk, the search
for food ingredients which effectively suppress postpran-
dial lipemia has increased in recent years. This rapid
measurement of chylomicron TAG is a valuable tool in
nutritional research for assessment of absorption of ex-
ogenous diet-derived lipids.
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[0057] The future perspectives in phenotyping for per-
sonalized nutrition and personalized drug treatment has
only just begun (14). To determine an individual’s ability
to clear postprandial lipids or the capacity of a food in-
gredient to diminish lipid uptake, TAG-rich lipoproteins,
and in particular chylomicrons must be measured after
an oral fat load. The new measurement technique out-
lined here facilitates ultra-rapid measurement of chylom-
icron TAGs and creates new opportunities for research
in lifestyle diseases and obesity.
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Claims
1. A method of preparing a regression model for pre-
dicting the quantity of a component of a lipoprotein
entity in a biological sample, the method comprising
the steps of:
- providing biological samples from a group of
non-fasting vertebrate subjects;
- quantifying the lipoprotein entity in the biolog-
ical samples using a reference quantification
method;
- recording NMR spectra of the biological sam-
ples;
- subjecting the NMR spectra to a global multi-
variate regression analysis;
- dividing the range of chemical shifts of the NMR
spectra into a number of intervals to obtain NMR
subspectra, each corresponding to a given in-
terval of chemical shifts;
- subjecting the NMR subspectra for each inter-
val of chemical shifts to a local multivariate re-
gression analysis;
- calculating error estimates for the global mul-
tivariate regression analysis and for each of the
local multivariate regression analyses for the li-
poprotein entity as quantified using the refer-
ence quantification method;
- selecting an interval of chemical shifts based
on a comparison of the error estimates of the
local multivariate regression analyses with the
error estimate for the global multivariate regres-
sion analysis; and
- calculating regression coefficients for the local
multivariate regression analysis corresponding
to the selected interval.
2. A method of predicting the quantity of a component
of a lipoprotein entity in a biological sample, the
method comprising the steps of:
- providing a biological sample from a non-fast-
ing vertebrate subject;
- recording a NMR spectrum of the biological
sample;
- selecting an interval of chemical shifts;
- comparing the NMR subspectrum correspond-
ing to the selected interval of chemical shifts with
a model employing regression coefficients ob-
tainable in a method according to claim 1;
- predicting the quantity of the component of the
lipoprotein entity by the use of the regression
coefficients.
3. A method according to claim 1 or 2, wherein NMR
spectra are proton or phosphorus NMR spectra.
4. A method according to any one of claims 1 to 3,
wherein the error estimate of the selected local mul-
tivariate regression analysis is lower than the error
estimate of the global multivariate regression anal-
ysis.
5. A method according to any one of claims 1 to 4,
wherein the interval of chemical shifts comprises the
lipid methylene and/or the methyl resonance(s).
6. A method according to any one of claims 1 to 5,
wherein the biological sample is blood, serum or
plasma.
7. A method according to any one of claims 1 to 6,
wherein the lipoprotein entity is a chylomicron.
8. A method according to any one of claims 1 to 7,
wherein the component of the lipoprotein entity is
triacylglycerol.
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9. A method according to any one of claims 1 to 8,
wherein the multivariate regression analysis is a par-
tial least squares (PLS) regression analysis.
10. A NMR analyser for predicting the quantity of a com-
ponent of a lipoprotein entity, the analyser compris-
ing
- a NMR spectrometer for recording a NMR
spectrum;
- a computer readable storage medium contain-
ing a regression model for predicting the quantity
of a lipoprotein entity prepared in a method ac-
cording to any one of claims 1 to 9, and computer
program code configured to predict the quantity
of the lipoprotein entity using the regression
model; and
- a data processor for executing the computer
program code.
11. A NMR analyser according to claim 10, wherein the
NMR spectrum is a proton NMR spectrum or a phos-
phorus NMR spectrum.
12. A NMR analyser according to claim 10 or 11, wherein
the lipoprotein entity is a chylomicron.
13. A NMR analyser according to any one of claims 10
to 12, wherein the component of the lipoprotein entity
is triacylglycerol.
14. A NMR analyser according to any one of claims 10
to 13, wherein the computer readable storage me-
dium further contains a model for predicting the risk
of a given subject for developing a disease based
on the prediction of the quantity of the lipoprotein
entity.
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